Agilent helps reveal variation in cancer cell lines

Skip to Navigation


  • Published: Jul 29, 2016
  • Author: Jon Evans
  • Source: Agilent Technologies
  • Suppliers: Agilent Technologies
  • Channels: Proteomics & Genomics / HPLC / Proteomics / Base Peak

Scientists using Agilent Technologies’ comparative genomic hybridization (CGH) technology have shown that cancer cell lines, which are broadly used in all aspects of biomedical research, may have vast differences in their genetic makeup, even when grown in the same batch.

As a result, the scientists have recommended that cell culture banks use advanced genomic technologies, such as array CGH, to ensure the consistency of the cells they provide to the research community.

Researchers have long been aware that some popular cell lines are not stable. That is, their biological properties and genetic makeup change as cultures are propagated in laboratories. While standard precautions and quality assurance methods are used to control such changes and validate authenticity of the cell lines, they may not be sufficient, according to a paper recently published in Scientific Reports.

This unexpected finding came out of a multi-year study aiming to develop a new generation of assays for testing environmental toxicity, involving a consortium of scientists from Agilent, Brown University, Georgetown University, Hamner Institutes and Johns Hopkins Bloomberg School of Public Health. The study, known as the Human Toxome Project, combines multiple '-omic' technologies, including liquid chromatography-mass spectrometry, and bioinformatics.

As part of this study, the scientists, led by Thomas Hartung at Johns Hopkins, selected the well-established breast cancer cell line MCF-7, known to be prone to spontaneous rearrangements, as their model system. In an effort to establish reproducibility, they conducted cell culture work at two independent sites using identical laboratory protocols.

They obtained the MCF-7 cells from the same cell bank and lot numbers, meaning they were grown in the same batch. Cells were validated using standard methods at the cell bank and at the project sites. However, despite extensive efforts to synchronize their protocols, the scientists were unable to obtain comparable results at the two sites.

They then accumulated cytological, transcript profiling and phenotypic evidence that the cells were actually different. Of particular importance, they found that the cells demonstrated vastly different responses to induction by the natural human hormone estrogen: one of the two cell lines was hypersensitive to estrogen, the other was not.

Using CGH technology from Agilent, the scientists confirmed that the two cell lines had vast differences in their genetic makeup, in some cases as large as entire human chromosomes.

The scientists concluded that existing methods for assuring the quality of cell cultures are insufficient. They recommend that advanced genomic technologies, such as array CGH, be broadly deployed by cell culture banks to ensure consistency of the cells they provide to the research community. For this project alone, the team estimated the additional costs of the unplanned experiments and delays to the project totaled around $1 million.

“Agilent’s array CGH platform is a leading technology used in hundreds of genomic and cytogenetic laboratories worldwide,” said Herman Verrelst, Agilent vice president and general manager of the company's Genomics Solutions Division and Clinical Applications Division. “We are pleased to see this example of using our technology to increase reproducibility of cell culture research. It is striking that a simple array CGH experiment, which would have cost less than $1000 at a commercial service provider, could have prevented $1 million in lost research funding and several years of delay.”

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in spectroscopy? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved